05:29 AM EDT, 10/22/2026 (MT Newswires) -- Verici Dx (VRCI.L) received an order from Asahi Kasei Therapeutics to provide biomarker testing for a phase 2 clinical trial evaluating an investigational therapy meant to prevent organ rejection in kidney transplant patients. The clinical diagnostics company will provide blood-based testing, including its pre-transplant risk assessment assay, as an exploratory research tool for the trial evaluating pegrizeprument, according to a Thursday release.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.